Skip to content
Head to head

UroGen Pharma Ltd vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: URGN · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

URGN +16.7%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
URGNVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price27.65515.02
Change today-12.86%-1.08%
1-year return+11.3%+22.0%
Market cap$1.36B$130.58B
52-week range16.50 – 50.81412.27 – 568.67
Valuation
P/E (TTM)-21.1133.14
P/E percentile, own 5-yr range4th99th
P/B-10.836.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.1915.32
Net profit (TTM)$-156.46M$3.88B
Revenue (TTM)$250.25M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+223.9%+11.8%
Gross margin91.4%85.5%
Operating margin-12.4%33.1%
Net margin-26.3%30.7%
Free cash flow (TTM)$-132.05M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership101.9%96.8%
Insider activity (12mo)31 buy / 19 sell28 buy / 22 sell
Short interest (% of float)10.4%1.9%
Analyst consensus100% buy (5)95% buy / 5% hold (21)
Analyst price target$62 (+125%)$624 (+21%)
StockVane view
StockVane Quant RatingD (52)C (68)
Company
Employees2916,400
Founded20041989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.